Shionogi & Co., Ltd.
Announcement Regarding the Consolidation of Shionogi-Apnimed Sleep Science, LLC as a Subsidiary
Shionogi & Co., Ltd. has resolved to acquire a 50% stake in Shionogi-Apnimed Sleep Science, LLC held by Apnimed for 100 million USD (approx. 15.952 billion JPY), making it a consolidated subsidiary.
Key Figures
- Acquisition Price: 100 million USD (equivalent in JPY: 15,952 million JPY)
- Equity Acquisition Ratio: 50.0% (before acquisition) → 100% (after acquisition)
- Acquisition Date: Scheduled for April 6, 2026
AI要約
Overview of Subsidiarization
At the Board of Directors meeting held on March 23, 2026, Shionogi & Co., Ltd. resolved to consolidate Shionogi-Apnimed Sleep Science, LLC (SASS), an equity-method affiliate, as a consolidated subsidiary. SASS was established in 2023 as a joint venture equally funded by Shionogi & Co., Ltd. and Apnimed, aiming to develop treatments for sleep disorders. Shionogi will acquire Apnimed’s 50% stake for 100 million USD (approx. 15.952 billion JPY) to increase its ownership to 100%. This move aims to fully leverage SASS’s R&D capabilities and intellectual property and enable more rapid decision-making.
Future Outlook and Impact
The impact on consolidated financial results for the fiscal year ending March 2026 is expected to be minimal. SASS currently generates no revenue and is advancing the development of treatment candidates SASS-001 and SASS-002 for obstructive sleep apnea syndrome. Shionogi positions the sleep disorder area as a key focus and plans to strengthen R&D as a mid- to long-term growth driver.
